Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

Danyang Li,Yigang Yuan,Chen Meng,Zihan Lin,Min Zhao,Liuzhi Shi,Min Li,Daijiao Ye,Yue Cai,Xiaofei He,Haige Ye,Shujuan Zhou,Haixia Zhou,Shenmeng Gao
DOI: https://doi.org/10.1186/s13148-024-01658-2
2024-03-28
Clinical Epigenetics
Abstract:miR-182 promoter hypermethylation frequently occurs in various tumors, including acute myeloid leukemia, and leads to low expression of miR-182. However, whether adult acute lymphocyte leukemia (ALL) cells have high miR-182 promoter methylation has not been determined.
oncology,genetics & heredity
What problem does this paper attempt to address?